Yahoo · Sep 28, 2026
Accuray partners with Samsung NeuroLogica on CyberKnife imaging
The agreements bring together mobile CT capabilities and precision treatment delivery expertise to improve anatomical visualisation during radiotherapy.
AR
NASDAQ · ARAY
Accuray Incorporated
Healthcare · Medical - Devices
$0.26
Down-$0.04 (-13.32%)
Updated Oct 7, 2026, 8:36 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 68.6M
- P/E ratio
- -1.94
- Dividend yield
- 0.00%
- 52-week range
- $0.22 – $0.50
- Volume
- 1.84M
- Avg. volume
- 1.04M
Price performance · ARAY
ARAY price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
ARAY closed at $0.26 after 21 trading sessions, down 0.19% for the selected period.
- Last close
- $0.26
- Period change
- -0.19%
- Period low
- $0.22
- Period high
- $0.30
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $0.3038 | $0.316 | $0.2615 | $0.2615 | 1.84M |
| Oct 5, 2026 | $0.2778 | $0.32 | $0.271 | $0.3017 | 2.21M |
| Oct 2, 2026 | $0.2627 | $0.3049 | $0.2574 | $0.281 | 4.68M |
| Oct 1, 2026 | $0.249 | $0.2879 | $0.2458 | $0.2672 | 2.67M |
| Sep 30, 2026 | $0.2843 | $0.29 | $0.27 | $0.2701 | 4.05M |
| Sep 29, 2026 | $0.2551 | $0.2993 | $0.2454 | $0.2955 | 12.88M |
| Sep 28, 2026 | $0.2877 | $0.382 | $0.284 | $0.2998 | 377.45M |
| Sep 25, 2026 | $0.23 | $0.23 | $0.2151 | $0.2151 | 760.47K |
| Sep 24, 2026 | $0.22 | $0.2296 | $0.22 | $0.223 | 911.69K |
| Sep 23, 2026 | $0.2368 | $0.2389 | $0.225 | $0.2255 | 389.33K |
| Sep 22, 2026 | $0.242 | $0.2456 | $0.23 | $0.23 | 471.45K |
| Sep 21, 2026 | $0.233 | $0.25 | $0.233 | $0.24 | 534.89K |
| Sep 18, 2026 | $0.236 | $0.2472 | $0.2312 | $0.2336 | 510.55K |
| Sep 17, 2026 | $0.23 | $0.2521 | $0.23 | $0.241 | 507.45K |
| Sep 16, 2026 | $0.233 | $0.248 | $0.2248 | $0.233 | 544.85K |
| Sep 15, 2026 | $0.243 | $0.2453 | $0.2301 | $0.2305 | 432.35K |
| Sep 14, 2026 | $0.2503 | $0.256 | $0.2439 | $0.2453 | 321.58K |
| Sep 11, 2026 | $0.25 | $0.27 | $0.2438 | $0.2502 | 698.39K |
| Sep 10, 2026 | $0.2567 | $0.2567 | $0.2377 | $0.243 | 622.76K |
| Sep 9, 2026 | $0.262 | $0.2638 | $0.25 | $0.2501 | 359.58K |
| Sep 8, 2026 | $0.266 | $0.2822 | $0.2601 | $0.262 | 433.72K |
Latest ARAY news
The latest Smart Investors Daily articles mentioning ARAY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ARAY research
Overview
Company profile and research snapshot.
Company profile
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 12, 2026 | Jefferies | Hold | — |
| May 7, 2026 | BTIG | Neutral | — |
| Feb 5, 2026 | BTIG | Buy | — |
| Nov 6, 2025 | BTIG | Buy | — |
| Aug 14, 2025 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 28, 2026
Why Is Accuray Stock Gaining Monday?
Accuray (ARAY) stock surged 42% premarket following a strategic CyberKnife imaging partnership with Samsung NeuroLogica.
Benzinga · Sep 28, 2026
Shares of South Korea ADRs, ETFs Rise Following Government Ban On Short Selling Through First Half of Next Year
Yahoo · Sep 27, 2026
Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform
Accuray Incorporated (NASDAQ: ARAY) today announced that it had entered into agreements with Samsung HME America, Inc., dba NeuroLogica Corp. ("Samsung NeuroLogica") to pursue advanced volumetric imaging capabilities for the CyberKnife® System. The announcement coincides with the American Society of Radiation Oncology (ASTRO) Annual Meeting in Boston, Massachusetts, where the companies are highlighting their collaboration. The collaboration represents another example of Accuray's strategy to add
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
